Johannes Rudolph
Papers
1
Total Citations
7
H-Index
1
About
Johannes Rudolph is a structural biologist and drug discovery researcher whose work centers on the molecular mechanisms of DNA repair and cancer therapeutics. His major contributions focus on the PARP1-HPF1 complex, a critical player in the DNA damage response. In his highly cited 2023 study on the HTS discovery of PARP1-HPF1 complex inhibitors, Rudolph addressed a key limitation of current PARP inhibitors (PARPi), which are effective primarily in BRCA-deficient cancers but suffer from resistance and narrow applicability. By targeting the newly discovered Histone PARylation Factor (HPF1), his work opens a novel avenue for expanding PARPi therapy to a broader range of tumors. This paper has already garnered 7 citations, reflecting its immediate impact on the field. Rudolph’s research bridges structural biology and translational oncology, offering a fresh strategy to overcome drug resistance. His findings are particularly notable for their potential to transform the treatment landscape for cancers beyond BRCA mutations, making him a rising figure in cancer drug discovery.
Research Focus
Key Achievements
Top Papers
- 1HTS discovery of PARP1-HPF1 complex inhibitors in cancer7 citations · 2023